Video

Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Author(s):

Sean Dowdy, MD

In Partnership With:

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.

Related Videos
Whitney Goldsberry, MD
Dimitrios Nasioudis, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Shaji Kumar, MD
Kathleen N. Moore, MD, MS
Shaji Kumar, MD
Kathleen N. Moore, MD, MS
Related Content
Breast cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 14th 2025

Researchers Resolve Uncertainty in BRCA2 Testing, Improving Cancer Risk Assessment and Patient Care

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Naseema Gangat, MBBS, of Mayo Clinic
January 13th 2025

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden

Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP
October 9th 2023

Expert Insights on the United States Chemotherapy Shortage

US FDA
January 2nd 2025

FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

Rafael Fonseca, MD
December 30th 2024

Working on the Frontlines of a Revolution in Multiple Myeloma Care